ArticleEuropean journal of clinical pharmacology2009
Persistence of antimuscarinic drug use.
Article in European journal of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Does electroacupuncture benefit mixed urinary incontinence? A systematic review and meta-analysis with trial sequential analysis.International urogynecology journal · 2022Pooled it
- Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis.Renal failure · 2019Pooled it
- Pooled it
- The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis.World journal of urology · 2018Pooled it
- Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis.Chinese medical journal · 2015Pooled it
- Posterior Tibial Nerve Stimulation With versus Without Mirabegron: A Randomized Controlled Trial.International urogynecology journal · 2024Trial
- Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder.Neurourology and urodynamics · 2023Trial
- Efficacy of solifenacin in the prevention of short-term complications after laparoscopic radical prostatectomy.The Journal of international medical research · 2017Trial
- OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.International journal of clinical practice · 2014Trial
- Use of sugammadex in prevention of post-operative urinary retention in minimally invasive hernia surgery.Hernia : the journal of hernias and abdominal wall surgery · 2024Article
- Mirabegron in the Management of Overactive Bladder Syndrome.International journal of women's health · 2022Review
- Percutaneous tibial nerve stimulation maintenance therapy for overactive bladder in women: long-term success rates and adherence.International urogynecology journal · 2021Article
- Overactive bladder in an integrated delivery system: a longitudinal cohort study.BMC health services research · 2020Article
- A Korean Postmarketing Study Assessing the Effectiveness of OnabotulinumtoxinA for the Treatment of Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder Using a Validated Patient-Reported Outcome Measure.International neurourology journal · 2019Article
- Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.PloS one · 2018Article
- Article
- Mechanisms of inhibitory action of TRK-130 (Naltalimide), a μ-opioid receptor partial agonist, on the micturition reflex.International urology and nephrology · 2017Article
- Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors.Investigative and clinical urology · 2017Article
- High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment.Medicine · 2016Observational
- Tolerability and persistence in a large, prospective case series of women prescribed mirabegron.International urogynecology journal · 2016Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEvidence suggests antimuscarinic drugs for the overactive-bladder syndrome only confer modest improvements in quality of life. We wanted to describe the persistence of therapy, including an extended analysis beyond the 1-year follow-up employed in other studies.
methodsAll prescriptions for drugs in ATC category G04BD were retrieved for the period 1999-2006 from a regional database with complete capture of all reimbursed prescriptions. Kaplan-Meyer curves were generated for duration of treatment for each substance and analyzed for determinants of termination.
resultsWith the exception of trospium chloride, all drugs had continuation rates of less than 50% at 6 months, less than 25% at 1 year, and less than 10% at 2 years and longer. Trospium chloride, however, exhibited continuation rates of 46% at 6 months, 36% at 1 year, 22% at 2 years, and 16% at 3 years.
conclusionsIn a setting of socialized medicine, we found higher continuation rates than previously published. Interestingly, we found that one of the older drugs on the market, trospium chloride, had a strikingly longer retention rate than other drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.